BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors for the treatment of various aggressive cancers. The company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion, and drug resistance. Its lead candidate, bemcentinib (BGB324), is under clinical development as a novel therapeutic agent for multiple types of cancer.